![Peter Anastasiou](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Peter Anastasiou
Geschäftsführer bei
HARMONY BIOSCIENCES HOLDINGS, INC.
Vermögen: - $ am 30.06.2026
Profil
Peter E.
Anastasiou is currently Director at Pharmaceutical Research & Manufacturers of America since 2017 and Chief Operating Officer at Harmony Biosciences Holdings, Inc. starting in 2026.
Former roles include Chief Executive Officer & Director at Capsida Biotherapeutics, Inc. from 2022 to 2025, Executive Vice President-North America at H.
Lundbeck A from 2009 to 2021, Marketing Director at Bristol Myers Squibb Co., Principal at Eli Lilly & Co., Vice President-Marketing at Neuronetics, Inc., and President at Lundbeck Seattle BioPharmaceuticals, Inc. Education includes an undergraduate degree from Albion College and an MBA from Kelley School of Business.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 02.04.2026 | 0 ( -.--% ) | - $ | 30.06.2026 |
Aktive Positionen von Peter Anastasiou
| Unternehmen | Position | Beginn |
|---|---|---|
| HARMONY BIOSCIENCES HOLDINGS, INC. | Geschäftsführer | 02.04.2026 |
Pharmaceutical Research & Manufacturers of America
 Pharmaceutical Research & Manufacturers of America BiotechnologyHealth Technology Provides pharmaceutical research and biotechnology services | Direktor/Vorstandsmitglied | 01.07.2017 |
Ehemalige bekannte Positionen von Peter Anastasiou
| Unternehmen | Position | Ende |
|---|---|---|
Capsida Biotherapeutics, Inc.
 Capsida Biotherapeutics, Inc. BiotechnologyHealth Technology Engages in the development of gene therapies for life threatening genetic disorders | Vorstandsvorsitzender | 01.10.2025 |
| H. LUNDBECK A/S | Corporate Officer/Principal | 31.12.2021 |
| ALDER BIOPHARMACEUTICALS, INC. | Präsident | - |
| ELI LILLY AND COMPANY | Corporate Officer/Principal | - |
| BRISTOL-MYERS SQUIBB COMPANY | Vertrieb & Marketing | - |
Ausbildung von Peter Anastasiou
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
63
Beziehungen ersten Grades
10
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 10 |
|---|---|
Bristol Myers Squibb Co.
 Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Eli Lilly & Co.
 Eli Lilly & Co. Pharmaceuticals: MajorHealth Technology Manufactures, wholesales and markets pharmaceutical products | Health Technology |
H. Lundbeck A/S
 H. Lundbeck A/S Pharmaceuticals: MajorHealth Technology Engages in the research, development, production and sale of pharmaceuticals for the treatment of brain diseases | Health Technology |
Neuronetics, Inc.
 Neuronetics, Inc. Medical SpecialtiesHealth Technology Develops and commercializes non-invasive therapies for psychiatric and neurological disorders | Health Technology |
Albion College
 Albion College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Pharmaceutical Research & Manufacturers of America
Pharmaceutical Research & Manufacturers of America BiotechnologyHealth Technology Provides pharmaceutical research and biotechnology services | Health Technology |
Lundbeck Seattle BioPharmaceuticals, Inc.
 Lundbeck Seattle BioPharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that specializes in research and develops transformative therapies for brain diseases | Health Technology |
Kelley School of Business
 Kelley School of Business Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Harmony Biosciences Holdings, Inc.
 Harmony Biosciences Holdings, Inc. Pharmaceuticals: MajorHealth Technology Develops and commercializes therapies for patients living with rare neurological disorders | Health Technology |
Capsida Biotherapeutics, Inc.
Capsida Biotherapeutics, Inc. BiotechnologyHealth Technology Engages in the development of gene therapies for life threatening genetic disorders | Health Technology |
Wählen Sie MarketScreener 
